Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
L Emmett, K Willowson, J Violet, J Shin… - Journal of medical …, 2017 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
cells that is revolutionising the way we image and treat men with prostate cancer. New small …
Theranostics in nuclear medicine practice
A Yordanova, E Eppard, S Kürpig… - OncoTargets and …, 2017 - Taylor & Francis
The importance of personalized medicine has been growing, mainly due to a more urgent
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …
need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic …
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
H Ahmadzadehfar, S Wegen, A Yordanova… - European journal of …, 2017 - Springer
Purpose Up to 30% of patients with castration-resistant prostate cancer (CRPC) do not show
any response to the first cycle of radioligand therapy (RLT) with [177 Lu] Lu-PSMA-617 (Lu …
any response to the first cycle of radioligand therapy (RLT) with [177 Lu] Lu-PSMA-617 (Lu …
The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
A Yordanova, A Becker, E Eppard, S Kürpig… - European Journal of …, 2017 - Springer
Abstract Background [177 Lu] Lu-PSMA-617 is a well-tolerated therapy for the treatment of
metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the …
metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the …
[HTML][HTML] Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095
A Afshar-Oromieh, U Haberkorn, C Zechmann… - European journal of …, 2017 - Springer
Purpose Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT)
was introduced in 2011. The first report described the antitumor and side effects of a single …
was introduced in 2011. The first report described the antitumor and side effects of a single …
[HTML][HTML] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu] Lu-PSMA-617 radioligand therapy
H Ahmadzadehfar, S Schlolaut, R Fimmers… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and
therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study …
therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study …
[HTML][HTML] Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
H Ahmadzadehfar, S Zimbelmann, A Yordanova… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Radioligand therapy with 177 Lu-PSMA-617 is an innovative and effective therapy for
castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone …
castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone …
From NETTER to PETTER: PSMA-targeted radioligand therapy
M Eiber, K Herrmann - Journal of nuclear medicine, 2017 - Soc Nuclear Med
In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting
retrospective German multicenter data (12 centers) on the performance of prostate-specific …
retrospective German multicenter data (12 centers) on the performance of prostate-specific …